S530
Clinical – Head & neck
ESTRO 2026
Radiotherapy and Radiation Oncology, Kliniken Maria Hilf, Moenchengladbach, Germany. 12 Department of Radiation Oncology, Freiburg University Medical Center, Freiburg, Germany. 13 Department of Radiation Oncology, Chemnitz Hospital, Chemnitz, Germany. 14 Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. 15 Department of Medical Informatics, Biometry and Epidemiology, , Friedrich-Alexander- Universität Erlangen-Nürnberg, Erlangen, Germany. 16 Department, Universitätsklinikum, Erlangen, Germany. 17 Comprehensive Cancer Center Erlangen- EMN (CCC ER-EMN), Universitätsklinikum, Erlangen, Germany. 18 Department of Otolaryngology - Head & Neck Surgery, Universitätsklinikum Erlangen, Friedrich- Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany. 19 Department of Oral and Maxillofacial Surgery, Universitätsklinikum Erlangen, Friedrich- Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany. 20 Department of Radiation Oncology, Universitätsklinikum, Erlangen, Germany Purpose/Objective: The DIREKHT trial is a prospective multicenter phase II trial investigating a de-intensified risk-adapted radiation. Long term tumor control and dysphagia Patients with newly diagnosed, non-metastatic HNSCC who had undergone surgery and presented with the following tumor stages (TNM 7th Edition) were eligible for omission of contralateral elective neck irradiation in the study: oral cavity and oropharyngeal cancers, pT1–3, pN0–2b, with a maximum of three ipsilateral lymph node metastases. Further information and initial results considering the whole patient population have already been published (DOI 10.3389/fronc.2024.1447123). In this analysis, we focus on patient groups with oral cavity cancer (N = 51) and oropharyngeal cancer (N = 89) who underwent ipsilateral elective neck irradiation. The main aim is to evaluate long-term tumor control rates and the risk of dysphagia following de-intensified radiotherapy, as dysphagia represents an important component of quality of life. Assessment is based on the Eating Assessment Tool (EAT-10) questionnaire and the dysphagia severity grade according to CTCAE v4.0. Results: Median Follow-Up time was 62 months. A total of 140 patients were included in the analysis. Overall locoregional recurrence rate at 5 years was 6.0% (95% CI [1.9; 9.9]. Cumulative incidence of 5-year locoregional recurrence in non-irradiated or dose- reduced regions was 3.0% (95%-CI [0.1; 5.8]. After five years, disease-free survival was 84.1% (95% CI [78.0; 90.6] and overall survival was 88.4% (95%-CI [83.0; rates are presented. Material/Methods:
logged into the app across 13 sessions and 64% would recommend it to other RT patients. Conclusion: These preliminary results suggest that capturing PROs remotely via a mobile app is feasible during and immediately after RT for HNC patients. It is minimally burdensome to patients across a range of demographics and has no impact on their perceptions of patient-centered communication. Future research using the app will investigate its efficacy in improving patients’ adherence to self- management strategies provided by their RT circle of care. Keywords: Patient-reported outcomes, Mini-Oral 239 De-intensification of postoperative radiotherapy in HNSCC by omitting contralateral elective neck irradiation– long term outcomes of the DIREKHT trial Charlotte Frei 1,2 , Jens von der Gruen 3,4 , Panagiotis Balermpas 3,4 , Claus Rödel 3 , Matthias G. Hautmann 5 , Felix Steger 5 , Thomas Hehr 6 , Carmen Stromberger 7 , Volker Budach 7 , Markus Schymalla 8 , Lukas Kocik 9 , Hans Geinitz 9,10 , Ursula Nestle 11,12 , Gunther Klautke 13 , Claudia Scherl 14 , Christine Gall 15 , Benjamin Frey 16,17 , Anna-Jasmina Donaubauer 16,17 , Philipp Schubert 16,17 , Anne Schützenberger 18,2 , Marco Kesting 19,2 , Stefanie Corradini 20,2 , Rainer Fietkau 2 , Sarina K. Mueller 18,2 , Marlen Haderlein 1,2 1 Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander- Universität Erlangen-Nürnberg, Erlangen, Germany. 2 Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Universitätsklinikum Erlangen, Friedrich- Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany. 3 Department of Radiotherapy and Radiation Oncology, University Hospital Frankfurt, Goethe- Universitat Frankfurt am Main, Frankfurt am Main, Germany. 4 Department of Radiation Oncology, Zurich University Hospital, Zurich, Switzerland. 5 Department of Radiotherapy and Radiation Oncology, University Hospital of Regensburg, Regensburg, Germany. 6 Department of Radiotherapy and Radiation Oncology, Marienhospital Stuttgart, Stuttgart, Germany. 7 Department of Radiotherapy and Radiation Oncology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt- Universität zu Berlin, Berlin, Germany. 8 Department of Radiotherapy and Radiation Oncology, University Hospital of Marburg, Marburg, Germany. 9 Department of Radiation Oncology and Radiotherapy, Ordensklinikum Linz Barmherzige Schwestern, Linz, Austria. 10 Faculty of Medicine, Johannes Kepler University Linz, Linz, Austria. 11 Department of
Made with FlippingBook - Share PDF online